New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 28, 2012
09:31 EDTWLP, ZBRAHouse Energy and Commerce Committee to hold a hearing
The Subcommittee on Health holds a hearing entitled, "Options to Combat Healthcare Waste, Fraud and Abuse" with participants Director Lavelle of Wellpoint and Senior Vice President Terzich of Zebra Technologies on November 28 at 10 am. Webcast Link
News For WLP;ZBRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
10:00 EDTZBRAOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Best Buy (BBY) upgraded to Outperform from Market Perform at Telsey Advisory... BlackRock (BLK) upgraded to Outperform from Market Perform at Bernstein... Cerner (CERN) upgraded to Outperform from Market Perform at Cowen... Community Health (CYH) upgraded to Outperform from Market Perform at Raymond James... Lockheed Martin (LMT) upgraded to Neutral from Sell at UBS... Teekay Offshore Partners (TOO) upgraded to Buy from Neutral at Citigroup... Trinity Industries (TRN) upgraded to Buy from Neutral at Longbow... Zebra Technologies (ZBRA) upgraded to Overweight from Neutral at JPMorgan... Ross Stores (ROST) upgraded to Hold from Sell at Maxim... St. Jude Medical (STJ) upgraded to Outperform from Market Perform at Cowen... Wolverine World Wide (WWW) upgraded to Buy from Neutral at DA Davidson... D.R. Horton (DHI) upgraded to Market Perform from Underperform at Raymond James... KB Home (KBH) upgraded to Market Perform from Underperform at Raymond James... Sony (SNE) upgraded to Overweight from Neutral at JPMorgan.
06:10 EDTZBRAZebra Technologies upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Zebra Technologies to Overweight citing a favorable risk/reward despite near-term integration risk from the Motorola enterprise business acquisition. The firm raised its price target for shares to $87 from $75.
November 14, 2014
08:04 EDTWLPWellPoint, Boehringer Ingelheim announce first project under collaboration
Boehringer Ingelheim Pharmaceuticals, WellPoint and HealthCore, announced that the companies are commencing a research project to identify and address unmet medical needs across populations of mutual interest. The first stage of the project will focus on non-valvular atrial fibrillation and will examine disease prevalence, treatment complications, such as hospital readmissions, and the use of evidence-based guidelines. This project is the first under the parties’ five-year research collaboration agreement, signed earlier this year. Information gathered through the NVAF project is intended to provide the basis for the collaborative development of healthcare interventions, which can be evaluated within WellPoint’s affiliated health plans and provider networks.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use